Cookson Peirce & Co. Inc. Acquires Shares of 11,331 Incyte Corporation $INCY

Cookson Peirce & Co. Inc. bought a new stake in Incyte Corporation (NASDAQ:INCY) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,331 shares of the biopharmaceutical company’s stock, valued at approximately $961,000.

A number of other hedge funds have also made changes to their positions in the company. Abich Financial Wealth Management LLC acquired a new position in Incyte in the third quarter valued at about $176,000. Assetmark Inc. increased its holdings in shares of Incyte by 94.2% during the third quarter. Assetmark Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 919 shares in the last quarter. Public Sector Pension Investment Board raised its stake in shares of Incyte by 20.5% in the third quarter. Public Sector Pension Investment Board now owns 14,277 shares of the biopharmaceutical company’s stock valued at $1,211,000 after acquiring an additional 2,429 shares during the last quarter. Savvy Advisors Inc. acquired a new position in shares of Incyte in the 3rd quarter worth approximately $442,000. Finally, LSV Asset Management grew its position in Incyte by 3.2% during the 3rd quarter. LSV Asset Management now owns 3,986,097 shares of the biopharmaceutical company’s stock worth $338,061,000 after acquiring an additional 124,266 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Price Performance

Shares of INCY stock opened at $101.10 on Friday. The stock has a 50-day moving average price of $101.73 and a 200 day moving average price of $94.07. The company has a quick ratio of 3.13, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. The firm has a market cap of $20.12 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 0.60 and a beta of 0.82. Incyte Corporation has a 12 month low of $53.56 and a 12 month high of $112.29.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The business’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.43 earnings per share. Research analysts expect that Incyte Corporation will post 4.86 EPS for the current year.

Insider Buying and Selling at Incyte

In other news, insider Thomas Tray sold 2,774 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $100.00, for a total value of $277,400.00. Following the transaction, the insider owned 22,973 shares of the company’s stock, valued at $2,297,300. This represents a 10.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the transaction, the executive vice president owned 66,132 shares in the company, valued at $7,213,017.24. This represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 95,225 shares of company stock valued at $9,519,745. 17.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on INCY. Weiss Ratings reiterated a “hold (c+)” rating on shares of Incyte in a research report on Thursday, January 22nd. Truist Financial set a $103.00 target price on Incyte in a research note on Wednesday, December 24th. Mizuho set a $121.00 price target on Incyte and gave the company an “outperform” rating in a report on Monday, December 8th. Guggenheim raised shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a report on Monday, November 3rd. Finally, Barclays raised their price objective on shares of Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Incyte currently has an average rating of “Hold” and an average target price of $103.94.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.